Text Size

Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2006 by Medical University of Warsaw.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Medical University of Warsaw
ClinicalTrials.gov Identifier:
NCT00453752
First received: March 28, 2007
Last updated: NA
Last verified: March 2006
History: No changes posted
  Purpose

The aim of this study was to assess serum N-terminal proBNP (NT-proBNP) in systemic sclerosis patients and to establish whether it reflects the severity of RV overload.


Condition
Systemic Sclerosis

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Medical University of Warsaw:

Estimated Enrollment: 100
Study Start Date: April 2006
Estimated Study Completion Date: April 2010
Detailed Description:

Elevated serum brain natriuretic peptide (BNP) levels released from myocytes of ventricles upon stretch have been found in patients with isolated right ventricular (RV) pressure overload. However, limited data suggest that serum BNP may be elevated in patients with systemic sclerosis (SSc), especially with RV dysfunction. The aim of this study was to assess serum N-terminal proBNP (NT-proBNP) in SSc patients and to establish whether it reflects the severity of RV overload.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Clinical diagnosis of systemic sclerosis

Exclusion Criteria:

  • Cardiovascular disorders other than pulmonary hypertension
  • Significant pulmonary function abnormalities
  • Impaired renal function
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00453752

Contacts
Contact: Ciurzyński Michał, M.D, Ph.D +48 22 502 11 44 mciurzyn@amwaw.edu.pl
Contact: Piotr Pruszczyk, M.D, Ph.D. +48 22 501 11 44 ppruszczyk@amwaw.edu.pl

Locations
Poland
Michał Ciurzyński Recruiting
Warsaw, Lindleya 4, Poland, 02-005
Contact: Michał Ciurzyński, M.D, Ph.D     +48 22 502 11 44     mciurzyn@amwaw.edu.pl    
Sponsors and Collaborators
Medical University of Warsaw
Investigators
Principal Investigator: Michał Ciurzyński, M.D., Ph.D Medical University of Warsaw
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00453752     History of Changes
Other Study ID Numbers: KB/66/2006
Study First Received: March 28, 2007
Last Updated: March 28, 2007
Health Authority: Poland: Ministry of Health

Keywords provided by Medical University of Warsaw:
systemic sclerosis
pulmonary hypertension
echocardiography
N-Terminal proBNP

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
 Connective Tissue Diseases
Skin Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013